{"meta":{"query_hash":"35f83303f269","filters":{"venue":"Blood Neoplasia"},"cohort_total":18,"direct_labels_cover":0,"predictions_cover":18,"exported":18,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/35f83303f269","api":"https://metacan.xera.ac/api/v1/cohort?venue=Blood+Neoplasia"},"results":[{"id":"W4399477840","doi":"10.1016/j.bneo.2024.100022","title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Johnson and Johnson; Janssen Scientific Affairs","keywords":"Ibrutinib; Hazard ratio; Medicine; Chronic lymphocytic leukemia; Internal medicine; Confidence interval; Dosing; Oncology; Adverse effect; Leukemia","score_opus":0.045808562921494676,"score_gpt":0.3896346356456451,"score_spread":0.34382607272415044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399477840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964868,0.00051335956,0.00008729298,0.00013961564,0.00020189505,0.0011785198,0.000047385874,0.000077506804,0.0012676425],"genre_scores_gemma":[0.9979816,0.00017746692,0.00064876414,0.000021245305,0.00049057155,0.000038192546,0.00014404797,0.00004745417,0.00045066274],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972371,0.00012802954,0.00077873806,0.00055677205,0.0007973284,0.00050205615],"domain_scores_gemma":[0.9984758,0.00049068365,0.00013121635,0.0005967747,0.0000913494,0.0002141955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005998266,0.0002803954,0.00080113934,0.001566498,0.000040968094,0.000035479447,0.00012261533,0.00015499364,0.0005538233],"category_scores_gemma":[0.00023114822,0.00022192771,0.0005702136,0.0030127743,0.00006112404,0.00009091461,0.000073608375,0.00031898785,0.000031927517],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24085349,0.015841544,0.12951326,0.0040730746,0.029680507,0.0073142257,0.008425496,0.52850944,0.013701403,0.0020656069,0.0028842834,0.017137652],"study_design_scores_gemma":[0.16537613,0.00319762,0.07676222,0.00086005795,0.0034932897,0.00008378718,0.000041632087,0.74617475,0.003379754,0.000098702854,0.00020579083,0.0003262902],"about_ca_topic_score_codex":0.0074572745,"about_ca_topic_score_gemma":0.0016937657,"teacher_disagreement_score":0.21766527,"about_ca_system_score_codex":0.007381917,"about_ca_system_score_gemma":0.004851844,"threshold_uncertainty_score":0.9991521},"labels":[],"label_agreement":null},{"id":"W4401959513","doi":"10.1016/j.bneo.2024.100039","title":"Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Solid organ; Pathological; Organ transplantation; Transplantation; Medicine; Lymphoma; Pathology; Internal medicine","score_opus":0.010411507844044439,"score_gpt":0.28176754517615193,"score_spread":0.2713560373321075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401959513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958635,0.008613286,0.000007897499,0.000250299,0.00019975731,0.00022083413,0.000036476733,0.00006654323,0.0010185476],"genre_scores_gemma":[0.99379337,0.004636408,0.0007207818,0.00016080249,0.00035795465,0.00003754493,0.000029910278,0.000018618854,0.00024458504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896586,0.00004221334,0.00031090793,0.00032690982,0.00016899504,0.00018510703],"domain_scores_gemma":[0.9995559,0.000115758274,0.000034930406,0.00013504416,0.00002842194,0.00012994409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011316299,0.00015789681,0.00031270267,0.00007081608,0.000028392664,0.00002794401,0.00003369617,0.00016422836,0.00008446513],"category_scores_gemma":[0.000013605336,0.00010897133,0.00014163108,0.0001295893,0.000073030504,0.00004581966,0.000017889075,0.00007633167,0.000018794399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046319855,0.0019364539,0.9730943,0.0005655814,0.00014177179,0.004383794,0.000712658,1.9745382e-7,0.00067370717,0.00011062676,0.0005952813,0.017322443],"study_design_scores_gemma":[0.0053016823,0.0010103836,0.98468953,0.00007339234,0.0015335137,0.0012425723,0.000036943737,0.000011605266,0.005652853,0.000043042786,0.00029306652,0.00011142323],"about_ca_topic_score_codex":0.000010157174,"about_ca_topic_score_gemma":0.0000084995645,"teacher_disagreement_score":0.017211022,"about_ca_system_score_codex":0.000014007483,"about_ca_system_score_gemma":0.00010497809,"threshold_uncertainty_score":0.4443722},"labels":[],"label_agreement":null},{"id":"W4402285270","doi":"10.1016/j.bneo.2024.100040","title":"BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"U.S. National Library of Medicine; American Cancer Society; Leukemia and Lymphoma Society; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Musculoskeletal Research Center, Washington University in St. Louis; Genome Technology Access Center","keywords":"Downregulation and upregulation; Pathogenesis; Mutant; Cell biology; Cancer research; Chemistry; Biology; Gene; Immunology; Genetics","score_opus":0.013893049665993942,"score_gpt":0.2695817774573835,"score_spread":0.25568872779138957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402285270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888868,0.0029985195,0.00053031236,0.0006888472,0.0003736932,0.0003742206,0.000029394922,0.00022479056,0.0058934256],"genre_scores_gemma":[0.9947745,0.0005385743,0.0010489048,0.000087094166,0.0004011166,0.000031505995,0.000036878813,0.00005719623,0.003024185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998215,0.000066597975,0.00027159482,0.00050520647,0.0005419033,0.00039967577],"domain_scores_gemma":[0.99903053,0.0003313476,0.000035466233,0.00028904638,0.00006996102,0.00024362869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028010862,0.00021465764,0.0002953871,0.00019030434,0.00006822425,0.00009771174,0.00009544088,0.00015937944,0.00017172337],"category_scores_gemma":[0.00007893887,0.00017493048,0.00008190073,0.00035832918,0.00010481088,0.000121790734,0.000091870876,0.0001842034,0.00020707409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021448055,0.00022450883,0.0042353035,0.00097594445,0.00028239138,0.0013292491,0.00069945416,0.000006343248,0.9740646,0.000832938,0.0013878241,0.015746959],"study_design_scores_gemma":[0.0078037316,0.0014366661,0.046367034,0.00081122405,0.0018659631,0.002549738,0.0006214008,0.017417964,0.88166744,0.0007035573,0.037910655,0.0008446084],"about_ca_topic_score_codex":0.00004494138,"about_ca_topic_score_gemma":0.000020941376,"teacher_disagreement_score":0.092397146,"about_ca_system_score_codex":0.00011460521,"about_ca_system_score_gemma":0.00046272093,"threshold_uncertainty_score":0.7133458},"labels":[],"label_agreement":null},{"id":"W4403348875","doi":"10.1016/j.bneo.2024.100045","title":"Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Irene Levi Sala Care Archaeological Foundation; Center for Individualized Medicine, Mayo Clinic; Gairdner Foundation; Mayo Clinic","keywords":"Germline; Multiple myeloma; Prospective cohort study; Oncology; Medicine; Center (category theory); Cohort; Internal medicine; Genetics; Biology; Gene","score_opus":0.00790845023562135,"score_gpt":0.25317451658200646,"score_spread":0.24526606634638512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403348875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961589,0.00047118886,0.000031445637,0.00005334181,0.000084955995,0.0021536893,0.00020167913,0.00007534774,0.0007694588],"genre_scores_gemma":[0.9975088,0.000051777024,0.0016221604,0.000024659654,0.000057039335,0.00020679961,0.00017563831,0.000052996675,0.00030010357],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980713,0.000054477714,0.00036387437,0.0005210569,0.0005440921,0.00044515936],"domain_scores_gemma":[0.9990552,0.00015252353,0.00006197459,0.00034671303,0.00017314997,0.00021043066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001319741,0.00024957274,0.00043871877,0.00029935827,0.00003392204,0.00001864691,0.000090557056,0.00010173042,0.00013143812],"category_scores_gemma":[0.00018251527,0.00017700745,0.0001002947,0.0004941814,0.00007815096,0.00012683324,0.000061345636,0.0002694568,0.00007266879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002121302,0.0025260467,0.9857882,0.00029238025,0.0007807297,0.0012685817,0.00038200276,0.0000028658762,0.002214886,0.000019115214,0.000026230962,0.004577604],"study_design_scores_gemma":[0.014459143,0.0012471477,0.9763521,0.00050435826,0.00029086843,0.00004144119,0.000024785044,0.0014505074,0.005383475,0.000018071038,0.00007982716,0.00014827566],"about_ca_topic_score_codex":0.00013034641,"about_ca_topic_score_gemma":0.00025585032,"teacher_disagreement_score":0.012337841,"about_ca_system_score_codex":0.0001011903,"about_ca_system_score_gemma":0.00021408267,"threshold_uncertainty_score":0.7218154},"labels":[],"label_agreement":null},{"id":"W4403707226","doi":"10.1016/j.bneo.2024.100052","title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Universitair Medisch Centrum Groningen; KWF Kankerbestrijding; AstraZeneca","keywords":"Epigenetics; Biology; Cell biology; DNA methylation; Cancer research; Epigenesis; Genetics; Gene; Gene expression","score_opus":0.008677332414844925,"score_gpt":0.24440063114828048,"score_spread":0.23572329873343556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403707226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861122,0.013075937,0.00028474783,0.000059037302,0.00016589096,0.000120533325,0.000013055202,0.0000060005273,0.00016261928],"genre_scores_gemma":[0.99742913,0.002153675,0.00020427833,0.000013445782,0.00010896982,0.000006875929,0.000028935972,0.0000100858515,0.000044585122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934244,0.00006551742,0.00020934273,0.00018445225,0.00009188205,0.00010634696],"domain_scores_gemma":[0.9997214,0.000053809803,0.00007693149,0.00008590322,0.00003283196,0.00002911365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016254034,0.00009018056,0.00010519135,0.00003239383,0.000033598073,0.000015222629,0.000084204476,0.00008735133,0.000018097915],"category_scores_gemma":[0.000025028523,0.00006299033,0.00005128755,0.0000673383,0.000059051235,0.0000023772825,0.000056782563,0.000065010965,0.0000010578284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014192484,0.000026530339,0.0035747208,0.000060803726,0.00007825577,7.722917e-7,0.000102061545,0.000115356146,0.99437433,0.000027817323,0.00007968603,0.0015454737],"study_design_scores_gemma":[0.00023619163,0.000184538,0.007830874,0.00001996592,0.00011950034,0.0000017352777,0.00004776258,0.0005045111,0.9904994,0.00008645607,0.0004002643,0.00006882075],"about_ca_topic_score_codex":0.0000060622424,"about_ca_topic_score_gemma":0.000002276011,"teacher_disagreement_score":0.011316969,"about_ca_system_score_codex":0.0000020314426,"about_ca_system_score_gemma":0.000033716697,"threshold_uncertainty_score":0.2568671},"labels":[],"label_agreement":null},{"id":"W4403707232","doi":"10.1016/j.bneo.2024.100050","title":"Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary","keywords":"Multiple myeloma; In vivo; In vitro; Pharmacology; Medicine; Chemistry; Biology; Internal medicine; Biochemistry; Biotechnology","score_opus":0.0566284165187802,"score_gpt":0.36746191264710704,"score_spread":0.31083349612832684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403707232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909134,0.006853788,6.724472e-7,0.00043538402,0.00012807889,0.0010649688,0.000027902504,0.000068359266,0.0005074501],"genre_scores_gemma":[0.9978122,0.0006939607,0.0006204667,0.000052433035,0.00014192762,0.0003221662,0.000011147657,0.000033877615,0.00031179347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793506,0.00016898103,0.00047274563,0.00059805735,0.00029914832,0.0005260327],"domain_scores_gemma":[0.9983977,0.001170173,0.000029102739,0.00018319736,0.00004322765,0.00017658141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036203186,0.00024101962,0.0005671982,0.00057027134,0.00003360392,0.00003233723,0.00006275238,0.00016259965,0.000015615651],"category_scores_gemma":[0.0010452133,0.00020048846,0.00007152806,0.00072263385,0.00015025116,0.00014011795,0.000115979376,0.00059391995,0.000028603823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039518448,0.0016522729,0.9144342,0.00062558224,0.00045257254,0.0083594015,0.0041559963,0.0000031259058,0.04828639,0.000014345265,0.00044021054,0.017624078],"study_design_scores_gemma":[0.031547777,0.001589673,0.7344831,0.0023200545,0.0001760737,0.000659106,0.0018470212,0.0040366547,0.22140649,0.00039696388,0.0010586674,0.0004783848],"about_ca_topic_score_codex":0.00032007578,"about_ca_topic_score_gemma":0.0041423035,"teacher_disagreement_score":0.17995104,"about_ca_system_score_codex":0.0001928032,"about_ca_system_score_gemma":0.00024539075,"threshold_uncertainty_score":0.8175682},"labels":[],"label_agreement":null},{"id":"W4406732078","doi":"10.1016/j.bneo.2025.100070","title":"Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; York University; McMaster University","funders":"","keywords":"Myeloid leukemia; Meta-analysis; Race (biology); Medicine; Randomized controlled trial; Oncology; Internal medicine; Sociology; Gender studies","score_opus":0.07367181825528708,"score_gpt":0.38412831072266646,"score_spread":0.3104564924673794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406732078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007729138,0.9813523,0.000023638622,0.000452142,0.000022448456,0.017260788,0.0005027656,0.00003513426,0.00034302013],"genre_scores_gemma":[0.000009553623,0.98625827,0.0006452016,0.00029993322,0.000025452724,0.0041880184,0.00029543802,0.000060451875,0.0082176905],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98410356,0.007835602,0.0058315117,0.000972032,0.000740584,0.0005166942],"domain_scores_gemma":[0.9794937,0.016277252,0.002438764,0.0013312738,0.00019727515,0.00026176914],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.016079124,0.0010003218,0.07901513,0.0019501336,0.000056499033,0.00007709108,0.00039797378,0.00065126905,0.00013996275],"category_scores_gemma":[0.015146706,0.00057811465,0.0077180066,0.002473033,0.00039002558,0.00009226143,0.00038006497,0.0010743703,0.0000063374596],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005061718,0.00004186488,7.121332e-7,0.6518168,0.3464386,0.00026531424,0.00003355315,4.2120128e-8,2.911744e-7,0.00009823609,0.0003127131,0.0004857436],"study_design_scores_gemma":[0.025121864,0.00004847331,5.735163e-7,0.14434059,0.8281352,0.0003576706,0.000010191594,0.0000041874523,0.0000022617846,0.000023244438,0.001666279,0.00028947747],"about_ca_topic_score_codex":0.0002460184,"about_ca_topic_score_gemma":0.000060132552,"teacher_disagreement_score":0.5074762,"about_ca_system_score_codex":0.00023731888,"about_ca_system_score_gemma":0.0016709819,"threshold_uncertainty_score":0.99966705},"labels":[],"label_agreement":null},{"id":"W4410267430","doi":"10.1016/j.bneo.2025.100115","title":"Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Menarini Group","keywords":"Chronic myelomonocytic leukemia; Medicine; Interleukin-3 receptor; Leukemia; Oncology; Phase (matter); Internal medicine; Cancer research; Chemistry; Myelodysplastic syndromes; Bone marrow","score_opus":0.03274721435044482,"score_gpt":0.349430216785658,"score_spread":0.3166830024352132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410267430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887426,0.0020288117,0.00028030825,0.00096079195,0.00016946359,0.004900591,0.00015798419,0.00013990598,0.0024878918],"genre_scores_gemma":[0.991277,0.00023136768,0.0010509219,0.00023589078,0.00024651163,0.0005765607,0.00013088425,0.00005628433,0.006194596],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99700797,0.00014269516,0.00086551777,0.0007459664,0.000514521,0.0007233212],"domain_scores_gemma":[0.9976082,0.00059556746,0.00021742645,0.0009935068,0.00038281735,0.00020249562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007733282,0.0003773975,0.0008739981,0.0005618755,0.00015670044,0.000031805946,0.00040750738,0.00023870383,0.000061445615],"category_scores_gemma":[0.000739808,0.0003210527,0.00028267506,0.0010768162,0.00016993767,0.0000893691,0.00014079246,0.0005575701,0.000022125987],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12029855,0.032153573,0.01448437,0.0031043822,0.010950947,0.0017857129,0.0068278196,0.0001370239,0.3939376,0.0009938093,0.11665937,0.29866686],"study_design_scores_gemma":[0.5324147,0.050155357,0.02564228,0.00090238266,0.0026947826,0.0002814342,0.0023085964,0.008434562,0.332676,0.000431272,0.04311297,0.00094569195],"about_ca_topic_score_codex":0.00029028815,"about_ca_topic_score_gemma":0.00012273542,"teacher_disagreement_score":0.4121161,"about_ca_system_score_codex":0.000840531,"about_ca_system_score_gemma":0.005006494,"threshold_uncertainty_score":0.9999242},"labels":[],"label_agreement":null},{"id":"W4410267432","doi":"10.1016/j.bneo.2025.100110","title":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Roche","keywords":"Myeloid leukemia; Refractory (planetary science); Medicine; Antibody; Bispecific antibody; Leukemia; Immunology; Oncology; Cancer research; Monoclonal antibody; Biology","score_opus":0.015639571765158587,"score_gpt":0.3125268000374506,"score_spread":0.296887228272292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410267432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756284,0.0006025601,0.000003929255,0.0010317118,0.00035508914,0.0011518322,0.00002100994,0.00003829148,0.009232758],"genre_scores_gemma":[0.98843473,0.00029178,0.00006942619,0.0001780014,0.00012649412,0.000035080182,0.000032630574,0.000024595469,0.0108072795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975513,0.00021180681,0.0006433226,0.0004644384,0.000702949,0.00042619],"domain_scores_gemma":[0.9986757,0.00025067962,0.00015042478,0.00066809915,0.00014074713,0.00011433851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035536516,0.00026559283,0.0005438604,0.00038922296,0.0001600889,0.000025486555,0.00035829245,0.00018072542,0.00012500754],"category_scores_gemma":[0.00011745996,0.00018121324,0.00018200174,0.0011400509,0.00015220631,0.000077597484,0.00025091122,0.0007306177,0.00004422187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001872183,0.0033626345,0.8824259,0.00024665063,0.00065903546,0.0002735853,0.0015517052,0.00005811162,0.10074113,0.0006069923,0.0019874584,0.006214622],"study_design_scores_gemma":[0.006410651,0.0009934842,0.9723224,0.0003081317,0.00033492252,0.000050142644,0.0006324955,0.00022316702,0.01202845,0.0001284245,0.006396669,0.00017107563],"about_ca_topic_score_codex":0.00076901074,"about_ca_topic_score_gemma":0.0006322325,"teacher_disagreement_score":0.0898965,"about_ca_system_score_codex":0.00013362645,"about_ca_system_score_gemma":0.0005355801,"threshold_uncertainty_score":0.7389661},"labels":[],"label_agreement":null},{"id":"W4410488748","doi":"10.1016/j.bneo.2025.100117","title":"Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Institut canadien d'information sur la santé; Princess Margaret Cancer Foundation; Ministry of Long-Term Care; Institute for Clinical Evaluative Sciences; Ministry of Health, Uganda; Ontario Ministry of Health and Long-Term Care","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Population; Survival analysis; Medicine; Oncology; Internal medicine; Environmental health","score_opus":0.004499670534224287,"score_gpt":0.2224345223380903,"score_spread":0.21793485180386601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410488748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99917734,0.00007635126,0.000007424331,0.000076972785,0.000036863596,0.00033941143,0.000035315654,0.000036439604,0.00021389124],"genre_scores_gemma":[0.99934876,0.0000036118054,0.00012594118,0.00020513221,0.000004077964,0.000027478593,0.00019775542,0.000011804431,0.00007541533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892443,0.000036534206,0.00025555413,0.00030968012,0.00023670019,0.00023707666],"domain_scores_gemma":[0.9993453,0.000179501,0.00007698995,0.00025643274,0.000046498484,0.00009528185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054794047,0.00020781824,0.0005093975,0.0004464221,0.0000696318,0.000028186636,0.000041203613,0.00007405206,0.000010904477],"category_scores_gemma":[0.00004192524,0.00014240906,0.000101124424,0.0006974538,0.000014007929,0.000055186378,0.000025829222,0.000039478804,0.0000017787166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001077639,0.007427507,0.9913293,0.00004536222,0.0006722827,0.000023344077,0.00012861229,0.000015647543,0.0000019175961,0.00004226246,0.0000040764235,0.00020192393],"study_design_scores_gemma":[0.046361204,0.00014284678,0.9507953,0.00005466649,0.002117076,1.899967e-7,0.00007707774,0.00010775681,0.00020579976,0.000003867565,0.00001622485,0.00011800054],"about_ca_topic_score_codex":0.0013373602,"about_ca_topic_score_gemma":0.0016562775,"teacher_disagreement_score":0.04625344,"about_ca_system_score_codex":0.00012358012,"about_ca_system_score_gemma":0.000099059536,"threshold_uncertainty_score":0.5807273},"labels":[],"label_agreement":null},{"id":"W4410488951","doi":"10.1016/j.bneo.2025.100118","title":"Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Montreal Heart Institute","funders":"Fondation Charles-Bruneau; Fondation Institut de Cardiologie de Montréal; Centre hospitalier universitaire Sainte-Justine; Canada Research Chairs; Fonds de Recherche du Québec - Santé; Cole Foundation; Ministère de l'Économie, de l’Innovation et des Exportations du Québec; Génome Québec; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada; Genome Canada","keywords":"Replication (statistics); Human leukocyte antigen; Cohort; Genome-wide association study; Population; Disease; Medicine; Biology; Immunology; Genetics; Virology; Internal medicine; Environmental health; Gene; Single-nucleotide polymorphism; Antigen","score_opus":0.006584351798126484,"score_gpt":0.22483287557123646,"score_spread":0.21824852377311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410488951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532706,0.0026546028,0.0010478327,0.00014913974,0.00010679547,0.00046740661,0.00004006266,0.000053507538,0.00015358099],"genre_scores_gemma":[0.9984491,0.000015423277,0.00061891816,0.00016793727,0.000013946485,0.000030099573,0.00011868137,0.000014164056,0.00057176396],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99876475,0.00014785957,0.00034332147,0.00044464588,0.000043398646,0.00025600265],"domain_scores_gemma":[0.9990324,0.00017136092,0.00021082681,0.00046763936,0.00008842348,0.00002937973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014934778,0.0001882993,0.00035614628,0.00011668278,0.0002088931,0.000022205935,0.00014343669,0.00017475501,0.000105990024],"category_scores_gemma":[0.00004927525,0.00016095508,0.00006646741,0.000161483,0.0002597991,0.00006170613,0.000041314903,0.00017937642,0.000010808332],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006977669,0.00018975466,0.448438,0.000032746553,0.00021765288,0.000007065818,0.000022300836,0.00006864241,0.5489352,0.00045761533,0.000025728454,0.00090755377],"study_design_scores_gemma":[0.010411214,0.00059910124,0.7854164,0.0003760346,0.001455913,0.00025520317,0.000047666163,0.00088660343,0.1981964,0.00043554595,0.0015081752,0.0004117495],"about_ca_topic_score_codex":0.0005350741,"about_ca_topic_score_gemma":0.000058514946,"teacher_disagreement_score":0.3507388,"about_ca_system_score_codex":0.000020958008,"about_ca_system_score_gemma":0.000298512,"threshold_uncertainty_score":0.6563558},"labels":[],"label_agreement":null},{"id":"W4411923937","doi":"10.1016/j.bneo.2025.100132","title":"Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Canada Research Chairs","keywords":"EIF4E; Biology; Genetics; Translation (biology); Gene; Messenger RNA","score_opus":0.005928059311746098,"score_gpt":0.22752285592108457,"score_spread":0.22159479660933848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411923937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98340046,0.01109951,0.000881219,0.0010015301,0.00097016426,0.00031933046,0.000102503975,0.00006869529,0.0021566085],"genre_scores_gemma":[0.99674,0.000061039376,0.000041715382,0.00036374858,0.0000022239046,0.00003438465,0.000050267878,0.0000102361455,0.0026964229],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988777,0.00011983346,0.00030301564,0.0002994532,0.000041390944,0.00035862686],"domain_scores_gemma":[0.9993394,0.00014929901,0.00008026621,0.0003136238,0.00011042477,0.0000070094297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014425268,0.00019281893,0.000375077,0.00023621763,0.00021611001,0.000011698923,0.00032942445,0.0002274403,0.00016834079],"category_scores_gemma":[0.000089911875,0.00019018081,0.00017207117,0.00043485017,0.00018777403,0.00007078264,0.000081416794,0.00018453924,0.0001527978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033796352,0.00051436905,0.0037102946,0.000036449426,0.00046699823,0.0000013652487,0.0001930854,0.00005547117,0.98192275,0.0059634554,0.0006916923,0.0061061373],"study_design_scores_gemma":[0.0028096777,0.00016228025,0.14510344,0.00009642527,0.00023623978,0.000009739549,0.00017154904,0.000005400998,0.80916125,0.0002600864,0.04178031,0.00020362287],"about_ca_topic_score_codex":0.00019176475,"about_ca_topic_score_gemma":0.00001801276,"teacher_disagreement_score":0.17276148,"about_ca_system_score_codex":0.000025657782,"about_ca_system_score_gemma":0.00020760922,"threshold_uncertainty_score":0.77553487},"labels":[],"label_agreement":null},{"id":"W4412907802","doi":"10.1016/j.bneo.2025.100148","title":"Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Growth inhibition; Leukemia; Cancer research; Chemistry; Biology; Genetics; Cell growth","score_opus":0.005888901129144163,"score_gpt":0.24525592257876533,"score_spread":0.23936702144962116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412907802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931418,0.0011228769,0.000031154363,0.0016829296,0.000027778615,0.00053249416,0.000008917796,0.0000615596,0.0033904957],"genre_scores_gemma":[0.9983101,0.0002696205,0.00076566375,0.0001965507,0.00004091813,0.000056848276,0.000015280442,0.000021049895,0.00032399915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985865,0.000100964324,0.00030909048,0.00031081334,0.00034954277,0.00034313486],"domain_scores_gemma":[0.9991102,0.00029212545,0.00011210072,0.00021311898,0.0001683258,0.00010409485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017372145,0.00019160305,0.00032684833,0.00018155876,0.00013042937,0.000029314862,0.00008227848,0.000018772495,0.000014650418],"category_scores_gemma":[0.00039294525,0.00012018706,0.000041436808,0.0005299357,0.00030217844,0.00012865079,0.00009140305,0.00033020903,0.0000023438458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011516315,0.00024385795,0.12327153,0.0008478429,0.00032310712,0.0013157309,0.0002624843,0.000035806814,0.86614573,0.003725822,0.00148441,0.0011920632],"study_design_scores_gemma":[0.0038174195,0.00077365816,0.012448957,0.00080355204,0.00022667162,0.0013221,0.00049166067,0.00012444446,0.97904074,0.0004495604,0.00035708767,0.00014413545],"about_ca_topic_score_codex":0.00019225027,"about_ca_topic_score_gemma":0.00013770878,"teacher_disagreement_score":0.11289504,"about_ca_system_score_codex":0.000028107826,"about_ca_system_score_gemma":0.00028775234,"threshold_uncertainty_score":0.4901086},"labels":[],"label_agreement":null},{"id":"W4413605538","doi":"10.1016/j.bneo.2025.100165","title":"Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre","funders":"Menarini Group","keywords":"Myelofibrosis; Medicine; Phase (matter); Targeted therapy; Oncology; Internal medicine; Chemistry; Bone marrow; Cancer","score_opus":0.026818573508397035,"score_gpt":0.31592032229977934,"score_spread":0.2891017487913823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413605538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249303,0.0012971922,0.00007070301,0.0010358937,0.00011248179,0.0034515625,0.0009102393,0.000061436076,0.0005674824],"genre_scores_gemma":[0.99639237,0.00046145305,0.0016898887,0.00023960856,0.00008309472,0.00031699287,0.00034605854,0.000026591384,0.00044391767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798566,0.00009569864,0.00070706656,0.000661359,0.00025645542,0.0002937348],"domain_scores_gemma":[0.99791193,0.0010862491,0.00020237338,0.00047753178,0.00017568424,0.00014622693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019495412,0.00033463378,0.00082432735,0.0001899682,0.0001702046,0.000029421275,0.00009711242,0.00012403248,0.000050054106],"category_scores_gemma":[0.00030781562,0.00025884263,0.0001520012,0.00033862854,0.00006803891,0.000051194987,0.000054362892,0.00013523255,0.0000030783926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17903572,0.1287212,0.37002057,0.00040402857,0.013545693,0.00030742618,0.01703064,0.000030889703,0.036974106,0.001080431,0.008329569,0.24451971],"study_design_scores_gemma":[0.2824469,0.021251984,0.5943384,0.0004974927,0.0023393165,0.000018859859,0.0011159474,0.00023538418,0.087528795,0.0001317975,0.009721906,0.00037320922],"about_ca_topic_score_codex":0.00033778627,"about_ca_topic_score_gemma":0.00015421728,"teacher_disagreement_score":0.24414651,"about_ca_system_score_codex":0.000030852138,"about_ca_system_score_gemma":0.00018056211,"threshold_uncertainty_score":0.99998635},"labels":[],"label_agreement":null},{"id":"W4413885244","doi":"10.1016/j.bneo.2025.100164","title":"Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"CD19; Refractory (planetary science); Lymphoma; Oncology; Medicine; Internal medicine; CAR T-cell therapy; Cancer research; Chimeric antigen receptor; Biology; Immunotherapy; Cancer","score_opus":0.025083253545016972,"score_gpt":0.320445708459025,"score_spread":0.29536245491400803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413885244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94537723,0.0032750515,0.000080350095,0.0006559585,0.00051824725,0.0021470974,0.00004714257,0.00015575829,0.047743134],"genre_scores_gemma":[0.9016338,0.0022194127,0.00045224448,0.000907168,0.000368428,0.00037359053,0.000121717414,0.000108295266,0.093815334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970832,0.00011543557,0.00060572295,0.00069466105,0.00053241575,0.00096855056],"domain_scores_gemma":[0.998114,0.0004264446,0.00011032786,0.0008851725,0.00023792482,0.0002261636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092569354,0.000400237,0.0007899906,0.0005532729,0.00013503472,0.000068040245,0.000353112,0.00037176305,0.0004399346],"category_scores_gemma":[0.00006283319,0.00036791115,0.00030136533,0.0008277727,0.00007328348,0.0001173486,0.00012079873,0.00040931097,0.00008823907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094164265,0.010178617,0.043047212,0.0006757572,0.00030975195,0.00020049461,0.0009616373,0.00000982941,0.92062664,0.000690824,0.007218414,0.0066643828],"study_design_scores_gemma":[0.08981885,0.0012877597,0.0048126234,0.00013097533,0.0001129242,0.000019394673,0.00028244208,0.00013401489,0.5452175,0.00013250622,0.35769743,0.0003536049],"about_ca_topic_score_codex":0.00042743713,"about_ca_topic_score_gemma":0.000500725,"teacher_disagreement_score":0.37540916,"about_ca_system_score_codex":0.00019866908,"about_ca_system_score_gemma":0.0011553831,"threshold_uncertainty_score":0.9998773},"labels":[],"label_agreement":null},{"id":"W4415973831","doi":"10.1016/j.bneo.2025.100182","title":"Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier","keywords":"Somatic evolution in cancer; Myeloid leukemia; Isocitrate dehydrogenase; Drug resistance; Leukemia; Myeloid","score_opus":0.01181312530648026,"score_gpt":0.24337750170542444,"score_spread":0.23156437639894417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415973831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400914,0.00028770405,0.0004336801,0.00012659017,0.000011280113,0.0007961327,0.00003173517,0.000025387884,0.004278328],"genre_scores_gemma":[0.99776894,0.000015918038,0.0013396702,0.00001949071,0.000018227302,0.00004604647,0.00006408773,0.000019232677,0.00070838927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983712,0.00008704119,0.0005229262,0.0003427832,0.00038321593,0.0002928564],"domain_scores_gemma":[0.99904674,0.00009080127,0.00017160879,0.0003927289,0.0002166161,0.00008151359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023354043,0.0001773592,0.00067342777,0.0015476628,0.00002425894,0.000005815244,0.00013047346,0.00015693298,0.000029449258],"category_scores_gemma":[0.000048243837,0.00014795846,0.00015337922,0.0031051512,0.00014029106,0.00007579035,0.00005979502,0.0002502961,0.000002623041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020899542,0.0017123666,0.4003433,0.0004063173,0.0019648261,0.00007501919,0.00033545497,0.005174606,0.58693403,0.00029287208,0.00013778478,0.00053344516],"study_design_scores_gemma":[0.012065133,0.0016027939,0.14781243,0.00051345193,0.005419394,0.000026698557,0.0003726919,0.03696289,0.7948001,0.00014509776,0.000032579574,0.0002467482],"about_ca_topic_score_codex":0.0010001833,"about_ca_topic_score_gemma":0.00036798348,"teacher_disagreement_score":0.25253087,"about_ca_system_score_codex":0.00036047588,"about_ca_system_score_gemma":0.0007222385,"threshold_uncertainty_score":0.6033571},"labels":[],"label_agreement":null},{"id":"W4416028285","doi":"10.1016/j.bneo.2025.100179","title":"Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bortezomib; Multiple myeloma; Proteasome; In vivo; Proteasome inhibitor; Cereblon; Cytotoxic T cell; Pomalidomide; Cell cycle","score_opus":0.0024778140326348914,"score_gpt":0.19639746734811725,"score_spread":0.19391965331548236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416028285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971578,0.00077596266,0.00007658832,0.0003342877,0.00008432961,0.00055804563,0.0000063471084,0.00001567318,0.0009909384],"genre_scores_gemma":[0.99834436,0.00007243309,0.00029216628,0.00039998168,0.00003844738,0.00008090123,0.000028341157,0.0000147033725,0.00072864525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991833,0.00007298365,0.00015877136,0.00029603345,0.00008348399,0.00020540244],"domain_scores_gemma":[0.9995547,0.000047961432,0.00004315128,0.00027626104,0.00002745182,0.000050476403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102235295,0.00015843584,0.00015870677,0.000050476337,0.00010661847,0.000041009724,0.00013776538,0.000087989494,0.000002545426],"category_scores_gemma":[0.00008941417,0.00010942978,0.000034656445,0.00015804321,0.00009211642,0.000006434002,0.000093426985,0.000098822245,0.0000033484002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006248632,0.00029014508,0.111864544,0.00012644289,0.00007173712,0.000038235656,0.00011323885,0.000025777808,0.8839033,0.0003043078,0.0009502105,0.0016871799],"study_design_scores_gemma":[0.0047424897,0.00038099027,0.08302753,0.00006167742,0.000038028862,0.00001738847,0.00007092341,0.00018600191,0.9087618,0.00003267298,0.002518484,0.00016200866],"about_ca_topic_score_codex":0.000054444397,"about_ca_topic_score_gemma":0.00039126162,"teacher_disagreement_score":0.028837016,"about_ca_system_score_codex":0.00000532115,"about_ca_system_score_gemma":0.00006594925,"threshold_uncertainty_score":0.44624168},"labels":[],"label_agreement":null},{"id":"W4416386731","doi":"10.1016/j.bneo.2025.100184","title":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Medical Council of Canada; Institute for Clinical Evaluative Sciences","keywords":"Mantle cell lymphoma; Chemoimmunotherapy; Rituximab; Retrospective cohort study; Lymphoma; Overall survival","score_opus":0.004504251309844768,"score_gpt":0.20126007053874237,"score_spread":0.1967558192288976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416386731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103415,0.00034841345,0.0000049344635,0.00015536557,0.000055819703,0.0005109113,0.000044812077,0.000023639386,0.007821942],"genre_scores_gemma":[0.9980838,0.00016765489,0.00035753546,0.000162525,0.000003872033,0.00004468205,0.00007144303,0.000014100372,0.0010944341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890447,0.00001573605,0.00031389395,0.00030289782,0.0002034715,0.00025952564],"domain_scores_gemma":[0.9995146,0.00007941482,0.000057497822,0.00022243433,0.000036759775,0.00008931991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004342847,0.00022491987,0.000525872,0.00021720318,0.000035038356,0.000011413934,0.00006278818,0.00009376337,0.000034426324],"category_scores_gemma":[0.0000023423154,0.00015896122,0.00006853799,0.00017742811,0.00004218611,0.000056109875,0.000012015224,0.0000607476,0.0000056836425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055715855,0.0034945689,0.9936597,0.0002053396,0.00023273802,0.00014866858,0.00069108506,0.0000021793605,0.0001152478,0.00012915838,0.00008176607,0.00068241777],"study_design_scores_gemma":[0.029254625,0.00046449684,0.94813544,0.00041369876,0.00068174023,0.000022818149,0.00003227722,0.0000033752647,0.020391017,0.000028551936,0.0004407866,0.0001311763],"about_ca_topic_score_codex":0.015767636,"about_ca_topic_score_gemma":0.046032533,"teacher_disagreement_score":0.045524236,"about_ca_system_score_codex":0.000078481346,"about_ca_system_score_gemma":0.0002738547,"threshold_uncertainty_score":0.99078643},"labels":[],"label_agreement":null}]}